Sichenzia Ross Ference LLP Represents Wize Pharma, Inc. in a $4.45 Million Private Placement
New York, NY – October 24, 2018 – Sichenzia Ross Ference LLP, announced today that it represented Wize Pharma, Inc. (OTCQB: “WIZP”), a clinical stage Israel based U.S. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common stock at $1.00 per share and 1,350 shares of newly created Series A preferred stock which is convertible at $1.00 per share.
The investors also received 100% 5 year Series A and 100% 6 month Series B warrants exercisable at $1.00 per share and $1.10 per share respectively. Wize received gross proceeds of $4.45 million.
The Sichenzia Ross Ference LLP team was led by Partner Gregory Sichenzia and Counsel Jeff Cahlon.
.jpg)
Sichenzia Ross Ference LLP
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Founding Partner Marc J. Ross, Esq. Presents Legal Webinar on The Business and Law of Marijuana - September 19, 2019
- Founding Partner Marc J. Ross, Esq. Speaks About Cannabis at NECANN New Jersey Cannabis Convention - September 19, 2019
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Bannerman Resources Limited on OTCQB Listing - September 18, 2019
